Mawson Infrastructure Group Inc. — Director's Dealing 2019

Dec 17, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wize Pharma, Inc. (WIZP)
CIK: 0001218683
Period of Report: 2019-12-13

Reporting Person: Danenberg Noam (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-13	Common Stock	C	752581	—	Acquired	952681	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-13	Warrants	$0.27	J	1505162	Acquired	2024-12-12	Common Stock (1505162)	Indirect
2019-12-13	Future Investment Rights	$0.27	J	31146	Disposed	2024-12-12	Common Stock (31146)	Indirect

Footnotes

F1: Outstanding debt converted at $0.27 per share.

F2: 752,581 shares held by Mobigo Inc. and 200,100 previously held shares directly.

F3: Exercisable five days following the public announcement of positive clinical data results for LO2A

F4: Securities held by Mobigo Inc.